Australia Markets closed

Grifols, S.A. (GIFLF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
18.880.00 (0.00%)
At close: 03:07PM EDT

Grifols, S.A.

Avinguda de la Generalitat, 152
Parc empresarial Can Sant Joan Sant Cugat del Vallès
Barcelona 08174
Spain
34 93 571 02 21
https://www.grifols.com

Sector(s)Healthcare
IndustryDrug Manufacturers—General
Full-time employees23,245

Key executives

NameTitlePayExercisedYear born
Mr. Raimon Grifols RouraCo-CEO & Exec. Director928.91kN/A1964
Mr. Víctor Grifols DeuCo-CEO & Exec. Director928.91kN/A1977
Mr. Alfredo Arroyo GuerraCFO & VPN/AN/A1958
Mrs. Eva Bastida TubauCorp. VP and Director of Scientific & Medical AffairsN/AN/AN/A
Ms. Nuria Pascual LapeñaVP of Corp. Treasury & Investor RelationsN/AN/A1964
Mr. David Ian BellGen. Counsel & Chief Corp. Devel. OfficerN/AN/A1955
Ms. Maria Teresa-Rioné LlanoVP of Corp. CommunicationsN/AN/A1966
Mr. Mateo Florencio Borrás HumbertCorp. VP & Chief HR OfficerN/AN/A1956
Mr. Francisco Javier Jorba RibesCorp. VP and Pres of the Biological Industrial GroupN/AN/A1951
Mrs. Montserrat Lloveras CalvoCorp. VP and Director of Corp. Accounting & ReportingN/AN/A1962
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Corporate governance

Grifols, S.A.’s ISS governance QualityScore as of 1 May 2022 is 4. The pillar scores are Audit: 6; Board: 3; Shareholder rights: 8; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.